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Abstract
Background As the world begins the rollout of multiple COVID-19 vaccines, pandemic exit
strategies hinge on widespread acceptance of these vaccines. In this study, we perform a
large-scale global exploratory study to examine the levels of COVID-19 vaccine acceptance
and explore sociodemographic determinants of acceptance.
Methods Between October 31, 2020 and December 15, 2020, 26,759 individuals were
surveyed across 32 countries via nationally representative survey designs. Bayesian methods
are used to estimate COVID-19 vaccination acceptance and explore the sociodemographic
determinants of uptake, as well as the link between self-reported health and faith in the
government’s handling of the pandemic and acceptance.
Results Here we show that intent to accept a COVID-19 vaccine is low in Lebanon, France,
Croatia, and Serbia and there is population-level polarisation in acceptance in Poland and
Pakistan. Averaged across all countries, being male, over 65, having a high level of education,
and believing that the government is handling the pandemic well are associated with
increased stated acceptance, but there are country-specific deviations. A belief that the
government is handling the pandemic well in Brazil and the United States is associated with
lower vaccination intent. In the United Kingdom, we find that approval of the first COVID-19
vaccine in December 2020 did not appear to have an impact on the UK’s vaccine acceptance,
though as rollout has continued into 2021, the UK’s uptake exceeds stated intent in large-
scale surveys conducted before rollout.
Conclusions Identifying factors that may modulate uptake of novel COVID-19 vaccines can
inform effective immunisation programmes and policies. Differential stated intent to accept
vaccines between socio-demographic groups may yield insights into the specific causes of
low confidence and may suggest and inform targeted communication policies to boost
confidence.
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Plain language summary
The aim of this study was to under-
stand what percentage of people
would accept a COVID-19 vaccine in
various countries across the world,
and to understand what groups of
people would be more or less likely to
accept the vaccine. We analysed the
response to surveys about people’s
intention to get a COVID-19 vaccine
performed in 32 countries, and find
that intent to accept a COVID-19
vaccine is comparatively low in
Lebanon, France, Croatia, and Serbia.
We also find that across all countries
considered, being male, older, or
having a high level of education is
associated with increased likelihood
to state a willingness to accept a
COVID-19 vaccine. By understanding
why different groups have differing
opinions about the COVID-19 vac-
cine, we may be able to better
understand specific concerns and
assist healthcare policymakers to
design more effective risk-
communication strategies.









The rollout of vaccines against the novel coronavirus disease(COVID-19) has begun to populations around the world.While large-scale vaccination manufacture, storage, supply,
and delivery all present noteworthy logistical challenges for suc-
cessful vaccination campaigns, addressing acceptance barriers to
COVID-19 vaccines needs equal attention.
Prepandemic evidence from the Vaccine Confidence Project’s
(www.vaccineconfidence.org) multinational studies of confidence
in vaccines suggests that older age groups are generally among the
most confident in vaccines1–4. The initial rollout of vaccines to
(predominately older age) high-risk groups across many settings
is unlikely to meet substantial resistance. Emerging evidence from
Public Health England and the Israeli Ministry of Health suggest
suggest higher rate of breakthrough infections than was expected
via clinical vaccine trials5,6; therefore, herd immunity may be
“vaccine-assisted” in the sense that vaccines substantially reduce
morbidity and mortality while population-level herd immunity
builds up through natural infection. However, pandemic exit
strategies are widely viewed as relying on achieving vaccination
levels that exceed those required for herd/community immunity,
which will require uptake from younger age groups, who are
among the least likely to state willingness to accept a COVID-19
vaccine in a variety of settings, including France7, Germany8,
Sweden8, United States9,10, and the United Kingdom11,12 (though
there is also evidence that younger age groups are more likely to
accept the vaccine in Mexico8). In addition, other factors such as
gender, education level, income, and ethnicity have been found to
be associated with intent to vaccinate in a range of large studies13.
To date, two multicountry studies exploring national intent to
accept a COVID-19 vaccine appear in the published literature,
exploring national-level differences in acceptance in June 2020 in
19 countries14 and from March to September 2020 in 12
countries8.
This study builds on the growing literature that explores
potential uptake of a novel COVID-19 vaccine by widening the
number of countries surveyed and by providing a more recent
appraisal of vaccine acceptance in many settings. This study also
includes countries that were surveyed after the Pfizer–BioNTech
vaccine had been submitted for emergency use authorisation15
and, in the United Kingdom, after this vaccine had both been
approved for use16 and the first patient vaccinated17.
In this study, intent to accept a COVID-19 vaccine is explored
for 26,759 individuals across 32 countries between October 21
and December 15, 2020, using data from the Worldwide Inde-
pendent Network of Market Research (WIN) World Survey. As of
25 January 2021, these countries represent 73% of the total global
mortality burden and among countries with recent and historic
vaccine confidence issues such as France18, Nigeria19, Pakistan20,
Poland21, United States22, and the United Kingdom23. A range of
possible drivers of COVID-19 vaccine acceptance are considered,
including sociodemographic status (sex, age, highest education
achieved, employment status, and income); self-reported health
(overall health and stress); and perceptions around government
handling of the pandemic. Country-level variables are used to
explore trends at the national level. A comparison is made
between the WIN World Survey data and 10,822 individuals
surveyed in June 2020 in 15 of the same countries as surveyed
here14. Time-varying trends in intent to accept a COVID-19
vaccine are assessed in the United Kingdom where previous
survey data11,24 allow a temporal comparison before and after the
approval and introduction of the Pfizer–BioNTech vaccine in the
United Kingdom.
We show that intent to accept a COVID-19 vaccine is relatively
low in Croatia, France, Lebanon, and Serbia, and highest in
Vietnam, India, China, and Denmark. We also find that being
male, older, and having a high level of education is associated
with higher intent to accept a COVID-19 vaccine, but there are
country-level variations around these global trends. Individuals
who believe that the government is handling the pandemic well
tend to be more inclined to vaccinate, except in Brazil and the
United States, where a belief that the government is handling the
pandemic well is associated with lower intent to vaccinate.
Methods
Data. Between October 31, 2020, and December 15, 2020, a total
of 26,759 individuals aged 18 years or older across 32 countries
were surveyed as part of WIN World Survey: Argentina, Brazil,
Canada, Chile, China, Croatia, Denmark, Ecuador, Finland,
France, Germany, Hong Kong, India, Indonesia, Ireland, Italy,
Japan, Lebanon, Malaysia, Mexico, Nigeria, Pakistan, Paraguay,
Peru, Poland, Serbia, Slovenia, South Korea, Spain, United
Kingdom, United States, and Vietnam. The WIN World Survey is
an international survey carried out by WIN every year to measure
people’s thoughts, expectations, and perceptions toward relevant
topics for society25. Surveys are collected via online surveys,
computer-assisted telephone surveys, and face-to-face interviews,
depending on, for example, countries’ internet penetration and
COVID-19 limitations see supplementary Table 1 for further
details on survey methodologies, sample sizes, and fieldwork
dates. In the survey, respondents are asked “When a vaccine for
the coronavirus becomes available, will you get vaccinated?”
There are four possible responses (henceforth denoted Y and
modelled as an ordinal four-vector): “definitely will get vacci-
nated” (4), “unsure but probably will get vaccinated” (3), “unsure
but probably will not get vaccinated” (2), and “definitely will not
get vaccinated” (1). In addition, individual-level socio-
demographic data on respondents’ sex, age, highest education
level, work status, and income quintile are collected as well as
individuals’ self-reported health (“how do you consider your
overall health in general?”) and stress (“how often would you say
that you suffer from stress?”). Individuals’ perceptions on how
their government has handled the pandemic (“please rate […] the
way your government [has] handled the [coronavirus] crisis”) are
also measured. To allow the statistical investigation into factors
that may affect country-wide variation in vaccination intent,
country-level data were collected on: the cumulative SARS-CoV-2
deaths per 100,000 population since the start of the pandemic
until the beginning of survey fieldwork in each country (deaths,
rather than cases, are used as deaths are likely a more robust
measure of the state of an epidemic as testing capacities may vary
more substantially across countries) and within the most recent
two weeks before fieldwork26; the Human Development Index
(HDI)27; GDP per capita (GDP)28; and confidence in the
importance of vaccines for children4. Estimates of country-level
confidence in the importance of vaccines for children4 are used as
a proxy for a country’s overall vaccine confidence as they show a
strong univariate association with parental acceptance of vaccines
for their children (and because there is a high collinearity between
national-level confidence in the importance of vaccines for chil-
dren and in other national-level confidence measures for the
safety and effectiveness of vaccines: collinearity may lead to
inflated confidence intervals around parameter estimates29). The
survey questionnaire is provided in the supplementary informa-
tion. We note that some variables collected were not of interest to
us in this exploratory study, for example, public views on the
health-system capacities and self-reported rates of smoking or
drinking.
During data collection, quotas aligning with national demo-
graphic distributions for age, sex, and subnational region were set
with survey weights calculated when quotas are not met so that
proportions of these demographic traits match national-level
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distributions. All surveys—with the exception of Ecuador and
Vietnam—are therefore nationally representative according to
national-level sex, age, and region demographic distributions. In
Ecuador and Vietnam, surveys took place in Quito-Guayaquil
(Ecuador) and Ha Noi and Ho Chi Minh City (Vietnam) and
quotas (and associated weights) were set to align with these
subnational regions. Data are collected using online surveys (25
countries, n= 20855 respondents), computer assisted telephone
interviews (four, n= 2803), telephone-assisted web interview
(one, n= 600), and face-to-face interviews (two, n= 2500), see
supplementary Table 1. Informed consent was obtained by WIN
for all survey participants.
Statistical analysis. National-level intent to accept COVID-19
vaccines is estimated using a categorical distribution with a
Dirichlet prior. The associations between individuals’ uptake
intent and individual- and country-level determinants are
obtained via Bayesian multilevel regressions30. Intent to accept
COVID-19 vaccines is related to sociodemographic data (sex, age,
highest education level, work status, and income quintile) and
self-reported health and stress, as well as perceptions on how
their government has handled the pandemic and the country-
level factors described in Data. Intent to accept a COVID-19
vaccine is related to these individual- and national-level covariate
data via Bayesian ordinal multilevel logistic regressions (detailed
below). A total of 95 respondents responded that they “do not
know” or provided no response as to whether they would get a
COVID-19 vaccine. To avoid the loss of missing data, these 95
responses are recoded to “unsure but probably will not get vac-
cinated” as they demonstrate some hesitancy about vaccinating,
but no strong intent to reject the vaccine. (A sensitivity analysis is
performed to test the robustness of this classification against
other classification methods, and this does not impact our find-
ings: see supplementary methods for further information).
There were five missing values for vaccination intent, these
responses (all from Vietnam) were removed from the analysis as
were seventeen unspecified values for covariate data (10 in
Germany for income and seven for age in Pakistan). These
missing data represent 0.09% of all responses. For all individual-
level covariates, a “do not know/ no response” category was
created for all covariates to again avoid the loss of missing data.
The reference group for individual-level covariates is an
employed, female, aged 18–24, with secondary education, in the
middle-income group, and who self-reports as healthy, not often
stressed, and thinks their government is handling the pandemic
badly (see Table 1). For most of these groups (and under our
exploratory analysis), there is no strong statistical reason for the
selection of the baseline category (e.g., males versus females).
However, with regard to employment, we selected the most
commonly selected employment option as the baseline group. For
income and education, it was of interest to examine the behaviour
of the extreme groups with regard to an “average” socio-
demographic group. As some country-level covariates are on a
different order of magnitude from each other (e.g., GDP and
HDI), all level-2 covariates are scaled to the unit interval using
s zð Þ ¼ zminðzÞmax zð ÞminðzÞ to aid prior specification and model
convergence.
Vaccination intent is modelled as
Yij  OrderedLogit xTijβj; τ1; τ2; τ3
  
, where Yij 2 f1; 2; 3; 4g is
vaccination intent for an individual i in country/territory
j ¼ 1; ¼ ; J ; xij 2 RP ´ 1 is an (indicator) matrix of P
individual-level covariates (which are provided by a binary—or
“one hot”—vector according to the sociodemographic status of
the individual); βj 2 RP ´ 1 are individual-level parameters;
and 1< τ1 < τ2 < τ3 <1. We use the ordered logistic distribu-
tion for k ordered outcomes specified by
Y  OrderedLogisticðμ;τ1; τ2; ¼ ; τk1Þ, where PY Y ≤ kð Þ ¼
σðτk  μÞ and σ xð Þ ¼ 1=ð1þ exÞ is the standard logistic sigmoid
function. This definition is equivalent to the proportional-odds
assumption, wherein the difference in the log of cumulative odds
ratios between successive categories is independent of the slope β.
Individual-level covariates are modelled as βjp  t γpz j; σ2p; 1
 
for p ¼ 1; ¼ ; P, where country-level covariates are specified in
the matrix z j2RQ ´ 1 (Q is the number of country-level covariates);
and γ2RP ´Q is the matrix of fixed-effect parameters. A t-
distribution is used to allow robust regression of country-specific
covariates. Semi-informative normal prior distributions are used for
all fixed-effect parameters γpq  Nð0; 10Þ. Half-normal hyperpriors
are placed over variance parameters, σp  Nþð0; 10Þ. These prior
widths (specified as variances) place the vast majority of prior mass
over plausible parameter values. All individual- and country-level
covariates and their recoding are provided in Table 2. To establish the
most parsimonious model for vaccine-uptake intent, three subsets of
the hierarchical model specified above are fit: (1) an intercept-and-
slopes-as-outcomes model (all model parameters, the “full” model);
(2) intercepts-as-outcomes (model 1, with γpq ¼ 0 if p > 1 and q > 1);
and (3) the “null” model (no level-1 or level-2 covariates)31. The
model with the lowest deviance-information criterion32 is determined
to be the most parsimonious model.
A Bayesian linear correlation is used to assess the relationship
between vaccination intent in the WIN World Survey and 10,822
individuals surveyed from 15 countries in June 2020 from
Lazarus14 (Brazil, Canada, China, Ecuador, France, Germany,
India, Italy, Mexico, Nigeria, Poland, South Korea, Spain, United
Kingdom, and United States)14,33. The survey question in that
study differs from the analysis here; respondents were asked to
reply to (on a scale from strongly agree to strongly disagree), “you
would accept a [COVID-19] vaccine if it were recommended by
your employer and was approved safe and effective by the
government.” The aim of this analysis is to show consistency in
estimates for national-level intent to vaccinate, despite
variation in survey wording. To show trends in the UK’s
acceptance of a COVID-19 vaccine, uptake estimates from
previous surveys (see Data) are presented with their correspond-
ing credible intervals.
Temporal trends in intent to accept a COVID-19 vaccine are
assessed in the United Kingdom before and after the first person
was vaccinated with the Pfizer–BioNTech vaccine in the United
Kingdom34 using similar survey data conducted in September24
(n= 1000) and October 202011 (n= 16820).
All inference is performed via Gibbs sampling, with models
implemented in JAGS (using R version 4.0.3). In total, 2000 burn-
in iterations and 20,000 iterations were sufficient for parameter
convergence for all models. Individual-level parameters are
reported as odds ratios (OR) or log odds ratios. All parameters
are reported with the corresponding 95% highest posterior-
density intervals (95% HPDIs). The 95% HPDI is the smallest
interval of the posterior distribution that contains 95% of the
probability mass. A breakdown of responses to vaccination intent
across all individual covariates for all countries can be found in
the supplementary data 1 and 2. Individual-level data and their
variable recodings are shown in Table 2. No ethical approval for
Lazarus14 data or WIN’s World Survey data was sought as these
datasets are in the public domain. Ethical approval for the UK
study data was obtained by the Imperial College ethics committee
on 15 June 2020 with reference 22130. In the UK dataset,
informed consent was obtained from all respondents before they
participated in the survey.
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Reporting summary. Further information on research design is
available in the Nature Research Reporting Summary linked to
this article.
Results
National-level estimates of vaccination intent. The overall intent
to accept a COVID-19 vaccine—that is, those replying that they
would either “definitely” or “probably” accept a COVID-19 vaccine—
is highest in Vietnam (96.8%, 95% highest posterior-density interval—
HPDI—95.3–98.2), India (90.7%, 88.1–93.2), China (90.6%,
88.8–92.3), and Denmark (87.0% 84.1–90.0), and the lowest in
Lebanon (44.1%, 39.5–48.2), France (44.0%, 41.1–47.3), Croatia
(41.5%, 37.5–45.5), and Serbia (37.8%, 33.6–42.1) (Fig. 1A).
Lebanon (42.6%, 38.4–47.0), Pakistan (31.8%, 28.7–35.1),
Paraguay (28.0%, 23.9–32.0), and Serbia (27.8%, 23.9–32.0) have
the highest proportion of respondents who state they will
“definitely not” take a COVID-19 vaccine (Fig. 1B). Vietnam
(69.3%, 65.2–73.0), India (57.8%, 53.5–62.1), Brazil (54.1%,
51.2–57.0), and Mexico (52.9%, 48.4–57.4) have the highest
proportion of respondents who say they will “definitely” take a
vaccine (Fig. 1B). There are six countries that have a higher
proportion of respondents who state they would “definitely not”
take the vaccine than would “definitely” take it: Croatia (22.4
versus 13.0%), France (23.9 versus 13.2%), Lebanon (42.8 versus
30.0%), Paraguay (27.9 versus 21.2%), and Poland (21.0 versus
19.6%) (Fig. 1C). Only a slightly higher proportion of
respondents in Pakistan (33.7 versus 31.9%) and Slovenia (20.0
versus 16.3%) would definitely get the vaccine than definitely not
(Fig. 1C).
Associations with vaccination intent. The intercepts-as-
outcomes model (see Methods) had the lowest DIC value
among all models. The fixed-effect individual- and country-level
determinants of intent to accept a COVID-19 vaccine are shown
in Fig. 2A. Only fixed-effect parameters for which the 95% HPDI
excludes zero are commented on. Averaged across all countries,
males are more likely to accept a COVID-19 vaccine than females
(odds ratio—OR—1.34 [95% HPDI 1.21–1.48]), over 65s are
more likely to accept than 18–24-year-olds (1.52 [1.26–1.85],
while 35-44-year-olds are less likely than 18–24-year-olds (0.84
[0.75–0.95]). (The odds ratio in this context is the odds of moving
to a higher level on the ordinal vaccination intent response for the
group in question compared with the same odds for the reference
group.) Those with higher education (undergraduate or post-
graduate degrees) are more likely to state intent to accept than
those with secondary education (1.24 [1.14–1.35]). Those
unemployed are less likely to state acceptance than those
employed (0.88 [0.79–0.98]), but students are more likely (1.19
[1.04–1.36]). High income is associated with increased intent
compared to low or middle income (1.23 [1.15–1.33]). A belief
that the government is handling the pandemic well is associated
with an increased intent to accept the vaccine (2.23 [1.91–2.63]).














count n % n % n % n % n %
Sex Female 13673 4404 32.2 4973 36.4 2464 18.0 1783 13.0 49 0.4
Male 13090 4952 37.8 4720 36.1 1949 14.9 1425 10.9 43 0.3
Age 18–24 3593 1322 36.8 1302 36.2 554 15.4 403 11.2 13 0.3
25–34 5623 1906 33.9 2090 37.2 841 14.9 756 13.4 29 0.5
35–44 5034 1580 31.4 1821 36.2 907 1.08 700 13.9 25 0.5
45–54 5041 1654 32.8 1831 36.3 934 18.5 607 12.1 14 0.3
55–64 4131 1470 35.6 1477 35.8 721 17.4 459 11.1 4 0.1
65+ 3337 1422 42.6 1170 35.1 454 13.6 283 8.5 7 0.2
Employment status Employed 16445 5786 35.2 5952 36.2 2706 16.4 1943 11.8 58 0.3
Unemployed 2955 856 29.0 1076 36.4 541 18.3 481 16.3 0 0.0
Housewife 2464 776 31.5 903 36.7 405 16.4 357 14.5 23 0.9
Retired/disabled 2838 1233 43.4 972 34.2 402 14.2 225 8.0 6 0.2
Student 1826 655 35.8 713 39.0 307 16.8 147 8.0 5 0.3
Refused or do not know (empl.) 234 50 21.4 77 32.9 52 22.2 55 23.5 0 0.0
Highest education Secondary 11489 3871 33.7 4209 36.6 1986 17.3 1379 12.0 43 0.4
Primary 1990 662 33.3 692 34.8 289 14.5 332 16.7 14 0.7
Higher 12536 4603 36.7 4593 36.6 2037 16.2 1272 10.2 31 0.2
None/other 553 171 31.0 132 23.8 60 10.8 187 33.7 4 0.7
Refused or do not know (educ.) 195 48 24.5 67 34.5 42 21.3 39 19.7 0 0.0
Income Medium/low 15343 5234 34.1 5629 36.7 2530 16.5 1895 12.3 56 0.4
High 8722 3391 38.9 3158 36.2 1306 15.0 844 9.7 24 0.3
Refused or do not know (inc.) 2688 730 27.1 902 33.5 574 21.4 469 17.5 13 0.5
Health Unhealthy 5400 1890 35.0 1963 36.4 953 17.6 570 10.6 24 0.4
healthy 21136 7415 35.1 7656 36.2 3417 16.2 2579 12.2 69 0.3
do not know (health) 227 51 22.3 75 33.0 43 18.9 59 25.9 0 0.0
Stress No 3481 1424 40.9 985 28.3 455 13.1 588 16.9 28 0.8
Yes 23076 7873 34.1 8651 37.5 3902 16.9 2588 11.2 63 0.3
Do not know (stress) 206 59 28.7 57 27.7 56 27.2 33 15.8 1 0.6
Gov’t handling Badly 12002 3326 27.7 3950 32.9 2541 21.2 2166 18.0 19 0.2
Well 13918 5906 42.4 5393 38.8 1670 12.0 885 6.4 63 0.4
Do not know (gov’t handling) 843 123 14.6 350 41.5 203 24.0 158 18.7 10 1.2
A summary of study factors and raw and breakdown of (weighted) vaccination intent by each covariate used in the study. Note that the total number of weighted responses (26,763) exceeds the total
number of respondents (26,759) by four.
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Respondents who did not provide a response or who did not
know their employment status or if the government was handling
the pandemic well had lower intent to vaccinate than the
respective baseline groups of employed and who thought the
government was handling the pandemic badly. Countries with a
higher more recent death count had a lower overall population
acceptance (0.31, 0.13–0.72).
There is some notable variation in country-specific parameters
(random effects) about the country-averaged (fixed-effect)
parameters. In Fig. 2B, random-effect parameters for which the
95% HPDI excludes zero are shown, thus revealing countries with
strong evidence to suggest a link between covariates and vaccine
intent. There is evidence to suggest that males are more likely to
accept the vaccine in 22 countries (Fig. 2B; SEX), with females in
China more likely to report intent to accept the vaccine than
males (−0.27, −0.53 to −0.03), and no evidence that males are
more likely than females (or vice versa) in nine countries. Over
65 s have a higher vaccination intent in 18 countries, with the
strongest effect size in the United Kingdom (1.28, 0.73–1.80)
(Fig. 2B; AGE). Paraguay is the only country for which those with
primary education are less likely to accept the vaccine than those
with secondary education. In 21 countries, higher education
(undergraduate or postgraduate degree) is associated with higher
vaccination intent than secondary education, with the strongest
effect found in the United States (0.53, 0.24–0.80) (Fig. 2B;
EDUCATION). Being retired or disabled is associated with
increased intent to vaccinate in Croatia, Denmark, Italy, and
United States relative to those employed, whereas being
unemployed in Chile, Japan, and Peru is associated with
decreased intent (Fig. 2B; EMPLOYMENT STATUS). Students
in two countries (Ecuador and Ireland) are more likely to accept
the vaccine. High income is associated with an increased intent in
24 countries (Fig. 2B; INCOME). Interestingly, the most
consistently informative variable of uptake intent is whether the
Table 2 Study data for Bayesian ordinal multilevel regressions to establish the determinants of intent to accept COVID-19
vaccines.
Survey item Values (recode in parenthesis) Regression baseline
Response variable COVID-19 vaccination intent (response)
When a vaccine for the coronavirus
becomes available, will you get vaccinated?
Definitely will get vaccinated (4), probably will get
vaccinated (3), probably will not get vaccinated (2),







Sex Male and female Female
Age 18–24, 25–34, 35–44, 45–54, 55–64, 65+ 18–24
Highest educational attainment None or only basic education (none/other), completed
primary school (primary), completed secondary school
(secondary), completed high level of education (higher),
completed higher level of education, e.g., master/PhD
(higher), other educational level (none/other), refused/do
not know/no response (do not know or refused,
education)
Secondary
Work status Working part-time (employed), retired/disabled, student,
working full-time (employed), housewife, unemployed,
refused/ do not know/ no response (do not know or
refused, work status)
Employed
Income Low (low/middle), medium low (low/middle), medium
(low/middle), medium high (high), high (high), refused/




How do you consider your overall health in
general?
Very healthy (healthy), healthy (healthy), somewhat
healthy (healthy), unhealthy, refused/do not know/no
response (do not know or refused, health)
Healthy
How often would you say that you suffer
from stress?
Very often (often), fairly often (often), sometimes (often),
occasionally (not often), never (not often), refused/do not
know/ no response (do not know or refused, stress)
Not often
Government handling
Very badly (badly), rather badly (badly), pretty well (well),





COVID-19 mortality (total deaths per
100,000 population preceding fieldwork)
Continuous variable scaled to the range [0, 1] n/a
COVID-19 mortality (total deaths per
100,000 population in two weeks
preceding fieldwork)
Continuous variable scaled to the range [0, 1] n/a
Human development index (HDI) 2019 Continuous variable scaled to the range [0, 1] n/a
Gross domestic product per capita (GDP) Continuous variable scaled to the range [0, 1] n/a
Vaccine confidence Continuous variable scaled to the range [0, 1] n/a
Questionnaire items from WIN World Survey are shown with possible responses and their recodes (individual-level covariates). Country-level covariate data definitions are also shown (country-level
covariates). The baseline for the hierarchical ordinal regression (see “Methods”) is shown for all covariates. (* A sensitivity analysis is performed to assess the impact that recoding “no response / do not
know” to “probably will not get vaccinated” has on our findings, see “sensitivity analysis” and supplementary Figs. 1 and 2 in the supplementary information for further details).
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government is handling the pandemic well. In 27 countries, a
belief that the government is handling the pandemic well is
associated with higher intent, while in Brazil and the United
States a belief that the government is handling the pandemic well
is associated with a lower intent, and in Pakistan, reported
uncertainty over the government’s handling is associated with
substantially lower vaccination intent (Fig. 2B; GOV’T HAND-
LING). There is no evidence to suggest that self-reported health
and self-reported stress were found to be associated with uptake
intent. All random-effect parameters are provided in supplemen-
tary data 1 and 2.
There is a correlation of ρ= 0.63 (95% HPDI, 0.34–0.88)
between intent to accept a COVID-19 vaccine in the WIN World
Survey data data and those from Lazarus14, which uses a different
question to probe respondents intended uptake if the vaccine was
deemed “safe and effective” by the government (see Fig. 3A and
Methods). India has a lower proportion of respondents stating they
would take a COVID-19 vaccine in Lazarus14 (74.5%, 72.4 to 76.6;
confidence interval generated assuming outcomes are binomially
distributed) than in the WIN data presented here (90.7%,
88.1–93.2). Due to slight differences in survey wording and survey
methodology, it is unclear whether this is a survey artifact or a
genuine increase in intent to accept the COVID-19 vaccine. Across
both studies, India, Mexico, South Korea, and China have the
highest stated willingness to accept a COVID-19 vaccine, while
France, Poland, and Nigeria have the lowest (Fig. 3A).
There is no evidence to suggest that vaccination views in the
United Kingdom have shifted after the introduction of the
Pfizer–BioNTech vaccine in the United Kingdom (Fig. 3B); in
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Fig. 1 Global trends in intent to accept a COVID-19 vaccine. A Ranking of countries by intent to accept a COVID-19 vaccine, with both positive responses
(“definitely will get vaccinated” and “unsure, but probably will get vaccinated”) grouped. Error bars denote posterior 95% highest posterior-density
intervals. B Ranking of countries by the percentage of respondents reporting that they will “definitely” not accept a COVID-19 vaccine, with all survey-
response possibilities shown. C For each country, the percentage of respondents who would “definitely” vaccinate is shown against the percentage who
would “definitely not” vaccinate, thus revealing countries that are polarised in their acceptance of a COVID-19 vaccine. (The diagonal line is y= x and thus
shows the line on which as many respondents would definitely accept the vaccine as would not.) Please see supplementary data 1 for all raw counts to
vaccination intent.
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Fig. 2 Determinants of intent to accept a COVID-19 vaccine. A The fixed-effect parameters (coloured: reds denote a negative log odds ratio, while blues
denote a positive log odds ratio) with 95% highest posterior-density intervals (HPDI; black horizontal bars) from the intercepts-as-outcomes model (see
Methods), which represents an “average” of the effects across all 32 countries (greyed). For each parameter, odds ratios and 95% HPDIs are shown (right
panel). The left panel denotes the covariate group with the baseline group shown in parentheses. B Random-effect parameters (coloured: reds denote a
negative log odds ratio, while blues denote a positive log odds ratio) from the intercepts-as-outcomes model. Only parameters whose 95% HPDIs exclude
zero are shown (these points are therefore a subset of the greyed points in A). (The left panel again shows the covariate group with the baseline in
parentheses. Note that not all covariates from (A) are shown as some do not contain random-effect parameters for which the 95% HPDI excludes zero.)
Countries are labelled with a two-letter abbreviation. Due to crowding of labels, not all data points have labels: the reader should consult supplementary
data 1 and 2 for all model parameters.
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2020 and 11–13 December 2020. In October, 47.5% (95% HPDI,
46.5–48.5) of UK respondents said they would “definitely” take a
COVID-19 vaccine compared with 47.7% (44.6–50.8) after
vaccine rollout began on 8 December; 32.6% (31.8–33.2) said
they were “unsure, but leaning towards yes” in October 2020
compared to 32.8% (29.9–35.8) who said they would “probably”
take the vaccine in December; 11.2% (10.7–11.8) said they were
“unsure, but leaning towards no” in October 2020 compared with
11.2% (9.3–13.1) (“probably not”); and 8.7 (8.2–9.2) and 8.4
(6.7–10.1) who would not take the vaccine. There was a slight fall,
however, in respondents who would “definitely” take the vaccine
between September and October 2020 (Fig. 3B).
Discussion
We conducted a global study on intent to accept a COVID-19 vaccine
in 32 countries and examined the individual- and country-level
determinants of vaccine uptake intent. There are a number of note-
worthy findings. There is substantial cross-country variability in
vaccine acceptance, with estimates ranging from 69.3% (65.2–73.0) of
respondents in Vietnam who would “definitely” accept the vaccine to
only 10.3% (7.6–13.0) in Serbia, 13.0% (10.3–15.8) in Croatia, and
13.0% (11.2–15.5) in France, which consistently has among the lowest
vaccine confidence globally4.
As high as 42.6% (38.4–47.0) of respondents in Lebanon and
31.8% (28.7–35.1) in Pakistan state they would “definitely not”
accept a COVID-19 vaccine. Confidence in vaccines has been
recorded as falling in the last few years in Pakistan, where a
history of vaccine scepticism has posed challenges for polio
eradication20. Lebanon is only one of five countries surveyed
where a belief that the government is handling the pandemic well
is not found to be associated with an increased likelihood of
vaccinating. A round-the-clock curfew implemented in Lebanon
on 14 January has led to protests against the government over
rising rates of unemployment35. As trust in government is a key
driver of vaccine confidence in many settings36–38, unsupported
policies could dent trust in the COVID-19 vaccination pro-
gramme: this relationship should be monitored closely, especially
in settings with relatively low intent to accept a COVID-19 vac-
cine or historically low confidence in governments or vaccines.
A belief that the pandemic is being handled well by the government
is associated with a lower intent to vaccinate in Brazil and the United
States (where the survey was conducted 11–18 November, after the
2020 US general election, but before the inauguration of Joe Biden). In
both countries, leaders have previously downplayed the threat of the
pandemic (which could, for instance, have affected supporters’ views
over the importance of a vaccine) and there have been previous
questions over whether Trump and Bolsonaro have been vaccine
sceptics39. While the former leader has seemed to embrace COVID-
19 vaccines (although is found to drive vaccine hesitancy40), the latter
recently stated that “…we’re not responsible for any [vaccine] side-
effects. If you turn into a crocodile, it’s your problem” and has
implied that he would not take a COVID-19 vaccine41. A recent study
in the United States found that those who favour the Republican
Party have lower COVID-19 vaccination intent than those who favour
the Democrat Party42, but we can find no studies investigating the
link between political preference and COVID-19 vaccine intent in
Brazil.
Intent to accept a COVID-19 vaccine appears to be polarised in
Poland and Pakistan. In these two countries, as many respon-
dents state they would “definitely” accept the vaccine (21.0%,
17.7–24.4 and 31.8, 28.7–35.1, respectively) than would “defi-
nitely not” accept it (19.6%, 16.5–23.0 and 33.7, 31.1–36.1,
respectively). Vaccination confidence appears to be declining in
both countries4, resulting possibly from recent and historic
misinformation20,43.
Additionally, we observed sex-, age-, education-, and income-
related associations with intent to accept a COVID-19 vaccine.
When an association was found between these variables and vac-
cine intent, it was predominately in the same direction for all
countries; however, there were some exceptions, such as females
being more likely to report a willingness to accept the vaccine in
China (whereas males were more likely to state acceptance in 22
countries). This finding contrasts with a global survey conducted in
June 202014 that found women to be generally more accepting,
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intent to accept a COVID−19 vaccine in the UK before and after
the first Pfizer−BioNTech vaccination administered in the UK
B
Fig. 3 Comparison of intent to accept a COVID-19 vaccine in this study to previous global and national surveys. A A comparison between overall intent
to accept a COVID-19 vaccine in this study (“probably or definitely”) versus agreement to “you would accept a [COVID-19] vaccine if it were
recommended by your employer and was approved safe and effective by the government”14 (see Methods for further details). B A comparison between
intent to accept a COVID-19 vaccine in the United Kingdom before (Lazarus14; de Figueiredo3) and after (this study) both emergency use authorisation by
the UK Medicines and Healthcare Products Regulatory Agency on 2 December 2020 and the first vaccination on 8 December 2020 (error bars denote
95% highest posterior-density intervals).
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study. The overall levels of acceptance in these 14 shared countries,
however, were found to strongly correlate Fig. 3A. Over 65s, those
with high education (undergraduate or postgraduate degrees) and
high-income groups were found to have a higher acceptance than
18–24-year-olds and low-/middle-income groups in the majority of
countries studied, in alignment with older age groups being more
confident in the safety and importance of vaccines in multiple
cross-country studies1,3. No association was found between self-
reported health and stress and vaccination uptake. A recent global
review of intended COVID-19 vaccine acceptance measured
via multinational and national-level studies identified four coun-
tries (Australia, United Kingdom, Ireland, and the United
States) where a link between self-reported health and COVID-19
vaccine intent was investigated, but only found a significant link
between health condition and vaccine intent in Ireland13.
We explored the link between national-level uptake intent and
national-level factors: we found no evidence of an association
between uptake intent and the Human Development Index, GDP
per capita, national-level vaccine confidence, and total COVID
deaths per 100,000 population. We did, however, find that
COVID deaths per 100,000 population in the prior two weeks to
fieldwork were negatively associated with uptake intent, that is,
that countries with more recent deaths had a lower overall vac-
cine acceptance. This result is challenging to explain, as we
demonstrate (Fig. 3A) that estimates of uptake intent have
remained relatively stable for at least 14 of the countries we
investigate between June 2020 and October–December, 2020.
Countries with high recent COVID-19 deaths at the time of
fieldwork included France, Slovenia, and Poland (that have low
overall vaccine confidence4); while, at the time of fieldwork,
China and Vietnam had the lowest two-week cumulative death
toll (www.worldometers.info, accessed of 31 January 2021), sug-
gesting that this effect could be dominated by the timing of
epidemic peaks in these respective countries.
A comparative study of surveys of vaccine intent in the United
Kingdom before and after the local approval of the
Pfizer–BioNTech vaccine reveals that the approval and intro-
duction of the vaccine had no impact on vaccination-uptake
intent, however, recent uptake figures in the UK of 88.0% for the
first dose44 are notably higher than stated intent among United
Kingdom adults in October 202011.
There are a number of study limitations to note. Only
individual-level covariates available in WIN World Survey were
available for analysis, and there may be a large number of factors
that could play stronger roles in determining uptake intent if
investigated (e.g., direct measurements of COVID-19 vaccine
hesitancy or distrust45, ethnicity46, risk perception47, or percep-
tions of feeling pressured48). Further, the estimates of uptake
provided here are static and could change drastically in response
to factors such as vaccine misinformation. Moreover, the online
nature of the surveys in the majority of countries may introduce
computer literacy or access biases that may impact the overall
estimates of vaccination intent. In countries where computer
access and literacy are high, we would expect these biases to be
small, but this is nonetheless a source of potential bias for
which we have not controlled. Social desirability biases may also
impact our estimates of intent to accept COVID-19 vaccines that
may also vary by mode of questionnaire (e.g., online versus tel-
ephone surveys)49. We have not attempted to control for
these potential biases but we do note that October 2020 survey of
intent to vaccinate in the United Kingdom made predictions
about vaccine uptake that slightly underestimated observed
uptake50.
A robust communication system that engages with the public
over issues of distrust and safety can help support acceptance of
COVID-19 vaccination and contribute to confidence building
around existing routine immunisation programmes, many of
which have been disrupted in the context of the COVID-19
pandemic. Tailored efforts to listen to and address the concerns
and issues among underserved or marginalised groups, will be
crucial to ensuring equity in national vaccination efforts. Losses
of trust in one vaccine can quickly drive uptake losses in other—
unrelated—immunisations4. Robust monitoring systems for vac-
cine confidence and misinformation can provide for the early
detection of losses in system confidence. Confidence issues can
then be addressed via clear communication strategies tailored to
specific socioeconomic or cultural groups that will respond dif-
ferently to both the message and type of messenger.
Data availability
All raw WIN World Survey data are available at https://winmr.com/win-world-survey-
covid19-vaccine-and-intention-to-travel-in-2021/, while cleaned data used in this study
can be found at https://osf.io/8vezs/. All data from Lazarus14 are available at https://
osf.io/kzq69. The UK data are from a previous large-scale study11. All source data for the
article figures can be found in supplementary data 3.
Code availability
The custom code to implement multilevel ordinal regressions can be found at https://
osf.io/8vezs/30.
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